STAT+: Moderna’s president weighs in on FDA’s decision not to review its flu vaccine

The FDA has reversed its earlier decision and will now review Moderna's mRNA-based flu vaccine, which it had previously declined. This change has been described as a "surprise rejection" and has raised concerns among experts regarding the implications for the vaccine industry. Moderna expressed optimism that its new flu shot could be available this year following the FDA's decision to review the vaccine. The reversal is seen as a positive development for drugmakers and vaccine developers, according to multiple sources, including CBS News and Stat News. Experts have noted that the FDA's actions may create a "destructive precedent" that could undermine future vaccine development in the U.S. The agency's decision to review the flu vaccine has been characterized as moving the goalposts on Moderna, leading to uncertainty for other vaccine developers. This situation reflects broader issues within the FDA, which has faced criticism for its handling of vaccine approvals. The implications of the FDA's reversal extend beyond Moderna, as it may affect the confidence of other pharmaceutical companies in the regulatory process. The FDA's actions have been characterized as indicative of chaos within the agency, highlighting ongoing challenges in its operations. The decision to review the flu vaccine is significant in the context of ongoing discussions about vaccine innovation and regulatory standards in the U.S. The complexities and challenges faced by the FDA in balancing safety, efficacy, and the need for timely vaccine availability are underscored by this situation.